Quarterly report pursuant to Section 13 or 15(d)

License Agreements - Additional Information (Detail)

v3.24.1.u1
License Agreements - Additional Information (Detail) - USD ($)
 3 Months Ended
Jan. 22, 2018
May 14, 2015
Mar. 31, 2024
Dec. 31, 2023
Jul. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Cash     $ 1,000,000    
Fair value of the contingent consideration     580,000 $ 528,000  
Loss on contingent consideration     52,000    
University of Bristol [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Maximum amount payable under license agreement, tied to milestones         $ 3,200,000
Payments under license agreement     125,000    
University of Bristol [Member] | Amendment to the University of Bristol License Agreement [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Maximum amount payable under license agreement, tied to milestones $ 1,700,000        
Payments under license agreement $ 37,500        
Sopharma [Member] | Share Purchase Agreement [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Percentage of outstanding shares acquired   75.00%      
Cash   $ 2,000,000      
Deferred payment   $ 2,000,000      
Fair value of the contingent consideration     600,000    
Loss on contingent consideration     $ 100,000